Cervical Cancer Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Cervical Cancer Market Summary
In 2023, the US led the cervical cancer market, valued at nearly USD 530 million, with most diagnoses occurring between ages 35-44 and an average diagnosis age of 50. While cases declined in the US and other 7MM countries over recent decades due to screening, a temporary rise occurred in 2021 during the COVID-19 pandemic. Japan, despite delayed HPV vaccination, reported fewer cases in 2023 versus 2020. Immunotherapy is emerging as a key treatment avenue, with biomarkers expected to guide patient selection. KEYTRUDA (pembrolizumab) became the first approved immune checkpoint inhibitor for cervical cancer, with additional advancements such as tisotumab vedotin (Pfizer/Genmab) under EMA review and KEYTRUDA's CRT combination approved for advanced stages in early 2024. Nykode's VB10.16 immunotherapy also entered Phase II trials. In 2023, the 7MM recorded about 40,600 incident cases, projected to decline by 2034, with the US holding the highest share. Key companies include Roche, Merck, BMS, Advaxis, and Zydus.

DelveInsight's "Cervical Cancer Market Insights, Epidemiology, and Market Forecast - 2034" report presents a comprehensive analysis of cervical cancer, encompassing historical and projected epidemiology, along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report details current treatment paradigms, emerging therapeutic options, market share by individual therapies, and the current and anticipated market size from 2020 to 2034, covering seven major markets. Additionally, it examines existing clinical management algorithms, key market drivers and barriers, and prevailing unmet medical needs, providing strategic insights to identify high-potential opportunities and evaluate the growth prospects of the cervical cancer market.

Explore the Evolving Cervical Cancer Market. Get DelveInsight's "Cervical Cancer Market Insights - 2034" for key trends, emerging immunotherapies, and growth opportunities in a USD 530M US market.@ Cervical Cancer Market Forecast - https://www.delveinsight.com/report-store/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Cervical Cancer Market Report are:
• According to DelveInsight, Cervical Cancer market size is expected to grow at a decent CAGR by 2034.
• The cervical cancer market size in the 7MM was approximately USD 930 million in 2023.
• The US accounted for the largest market size of cervical cancer, i.e., nearly USD 530 million in 2023.
• Leading Cervical Cancer companies working in the market are ADC therapeutics, Roche, AstraZeneca, Precigen, Puma Biotechnology, Iovance Bio therapeutics, Nykode Therapeutics, ISA Pharmaceuticals, Regeneron, Transgene, Daiichi Sankyo, Merck Sharp & Dohme, Genmab/Pfizer, Advenchen Laboratories, ImmunityBio, Calithera Biosciences, Seagen, Akeso, Verastem, Iovance Biotherapeutics, Xencor and Many Others.
• Key Cervical Cancer Therapies expected to launch in the market are TECENTRIQ (atezolizumab), Volrustomig, AL3818, ANKTIVA (N-803), ZEJULA (niraparib), Telaglenastat, JEMPERLI (dostarlimab) + cobolimab, TUKYSA (tucatinib), Cadonilimab, Avutometinib, LN-145, Vudalimab, ENHERTU (trastuzumab deruxtecan), and others.
• In July 2025, Tisotumab vedotin (Tivdak), an innovative antibody-drug conjugate (ADC), marks a notable advancement in the treatment of recurrent cervical cancer. This tissue factor-targeting therapy signifies a shift in the current treatment landscape, offering better outcomes in progression-free and overall survival compared to traditional chemotherapy. The study reported an increase in response rates from 5% to 17%. However, experts note that while these results are encouraging, the survival benefits-1.5 months in progression-free survival and 2 months in overall survival-remain modest, underscoring the need for continued progress in cervical cancer treatment.
• In June 2025, Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of persistent, recurrent, or metastatic cervical cancer, in combination with platinum-based chemotherapy, with or without bevacizumab. The NMPA approval marks the third approved indication for cadonilimab.
• In March 2025, Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic cervical cancer.
• In March 2025, Shanghai Henlius Biotech announced results of a Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Cervical Cancer (CC) Failed or Intolerance to Standard First-Line Therapy
• In February 2025, Seagen Inc announced results of a Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
• In February 2025, Bio-Thera Solutions announced results of a Phase II/III Study to Evaluate the Safety and Efficacy of BAT1308 Combined with Platinum-Based Chemotherapy ± Bevacizumab As First-Line Therapy for PD-L1-Positive (CPS ≥ 1) Persistent, Recurrent or Metastatic Cervical Cancer
• On December 3, 2024, Corbus Pharmaceuticals Holdings, Inc. revealed that the FDA had awarded Fast Track designation to CRB-701 for treating relapsed or refractory metastatic cervical cancer.
• In October 2024, Sichuan Baili Pharmaceutical Co., Ltd. Announced results of a Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
• In February 2024, Pfizer and Genmab revealed that the European Medicines Agency (EMA) had accepted the marketing authorization application for tisotumab vedotin as a treatment for adult patients with recurrent or metastatic cervical cancer who experienced disease progression after first-line therapy.

Cervical Cancer Overview
Cervical cancer is a malignant tumor that develops in the cells of the cervix, the lower part of the uterus that connects to the vagina. It is primarily caused by persistent infection with high-risk strains of the human papillomavirus (HPV), a common sexually transmitted infection. While the immune system typically clears HPV infections, in some cases, the virus can lead to abnormal cell changes that progress into cancer over time. Early-stage cervical cancer may not cause noticeable symptoms, but as the disease advances, symptoms such as abnormal vaginal bleeding (especially after intercourse), pelvic pain, pain during urination, and unusual vaginal discharge may occur. Diagnosis is typically confirmed through a Pap smear, HPV testing, colposcopy, and biopsy. Imaging tests like MRI, CT scans, and PET scans help determine the cancer's stage and extent. Cervical cancer Treatment options depend on the stage of the disease and may include surgery (such as hysterectomy), radiation therapy, chemotherapy, targeted therapy, or immunotherapy. Preventive measures such as routine Pap smears, HPV vaccination, and safe sexual practices significantly reduce the risk of developing cervical cancer. Despite being a preventable and treatable disease when detected early, cervical cancer remains a major health concern, particularly in low-resource regions with limited screening programs

Learn more about Cervical Cancer treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Cervical Cancer Treatment Market - https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cervical Cancer Market Outlook
In 2023, the cervical cancer market size in the 7MM reached ~USD 930 million, projected to grow through 2034, with Germany leading the EU4+UK market. By 2034, KEYTRUDA is expected to generate the highest revenue. Key players-AstraZeneca, Roche, Precigen, and Nykode Therapeutics-are at the forefront of advancing innovative therapies, with ongoing research promising continued market expansion and improved patient outcomes.

The cervical cancer therapeutics market is driven by a robust pipeline with novel mechanisms of action and rising incidence rates. Current treatment for unresectable, locally advanced cases often involves chemoradiotherapy (CRT), though this can cause long-term toxicities and poor outcomes after recurrence. For persistent, recurrent, or metastatic disease, treatment has shifted from platinum-based chemotherapy doublets to cisplatin-paclitaxel plus bevacizumab (AVASTIN), FDA-approved in 2014 as the first late-stage therapy since 2006. The emergence of biosimilars, such as Amgen's MVASI (the first US cancer biosimilar approved in 2017), is reshaping cost dynamics. Targeted therapies and immunotherapies, including tisotumab vedotin (TIVDAK) and KEYTRUDA, are setting new benchmarks, with TIVDAK advancing toward earlier-line use despite ocular toxicity warnings. Precision medicine is increasingly central, supported by biomarker-driven approaches.

Cervical Cancer Epidemiology
In 2023, the 7MM reported approximately 40,600 incident cases of cervical cancer, with numbers expected to decline over the forecast period. The United States represented the largest share, contributing around 34% of the total incident population. Within the US, squamous carcinoma accounted for nearly 9,000 cases by histology. Stage-specific analysis revealed that Stage IB had the highest incidence, followed by Stage IVB. Across the EU4 and the UK, Germany recorded the highest number of cervical cancer cases, followed by the United Kingdom, while Spain reported the lowest incidence in 2023.

Cervical Cancer Epidemiology Segmented by:
• Total Incident Cases of Cervical Cancer in the 7MM
• Stage-specific Incident Cases of Cervical Cancer in the 7MM
• Histological type-specific Incident Cases of Cervical Cancer in the 7MM
• Age-specific Incident Cases of Cervical Cancer in the 7MM

Discover detailed insights into Cervical Cancer epidemiology, trends, and segmentation across the 7MM. Explore stage-wise, histology-specific, and age-specific data to identify key market opportunities and regional dynamics.@ Cervical Cancer Patient Pool - https://www.delveinsight.com/report-store/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cervical Cancer Market Drivers
• Rising Incidence in Certain Regions: Continued high prevalence in low- and middle-income countries sustains demand for effective therapies.
• Advancements in Treatment Modalities: Introduction of targeted therapies, immunotherapies, and ADCs like TIVDAK improves outcomes.
• Robust R&D Pipeline: Novel agents with unique mechanisms of action (e.g., Volrustomig, PRGN-2009) are expected to shift treatment dynamics.
• Regulatory Milestones: Approvals like AVASTIN and KEYTRUDA for advanced cervical cancer have expanded treatment options.
• Precision Medicine Approaches: Increased biomarker-driven treatments (e.g., PD-L1 expression) enable personalized therapy selection.
• Growing Adoption of Biosimilars: Cost-effective alternatives, such as MVASI, improve treatment accessibility.

Cervical Cancer Market Barriers
• Treatment-Related Toxicities: CRT and certain targeted therapies cause significant side effects impacting quality of life.
• High Recurrence Rates: Persistent and recurrent disease after standard treatments remains a major challenge.
• Limited Options for Advanced Stages: Few approved drugs for late-line settings restrict patient outcomes.
• Economic Burden: High costs of novel therapies and immunotherapies limit accessibility, particularly in resource-limited settings.
• Biomarker Limitations: Not all patients express necessary biomarkers (e.g., PD-L1), restricting eligibility for certain treatments.
• Uneven Screening and Vaccination Coverage: Inconsistent preventive measures contribute to regional disparities in disease burden.

Cervical Cancer Pipeline and Drugs Uptake
Volrustomig: AstraZeneca
AstraZeneca's Volrustomig is a bispecific monoclonal antibody targeting PD-1 and CTLA-4, delivered intravenously. It is currently in a Phase III trial (eVOLVE-Cervical; NCT06079671) assessing its efficacy and safety in women with high-risk, locally advanced cervical cancer (FIGO 2018 stage IIIC-IVA with lymph node involvement) who remain progression-free after platinum-based CCRT. The first regulatory filing is anticipated post-2025.

PRGN-2009: Precigen
Precigen's PRGN-2009 is a novel, replication-incompetent gorilla adenovirus therapy designed for HPV-associated cancers. It utilizes the company's UltraVector and AdenoVerse platforms to deliver HPV 16/18 antigens, enabling repeated dosing without increasing neutralizing antibodies. Following FDA clearance in May 2023, a Phase II trial (NCT06157151) is underway to compare PRGN-2009 plus pembrolizumab against pembrolizumab monotherapy in pembrolizumab-resistant recurrent or metastatic cervical cancer. A completed Phase I trial (NCT04432597) demonstrated positive safety and efficacy results in both monotherapy and combination arms, with findings presented at the 2023 ASCO annual meeting.

Cervical Cancer Pipeline Development Activities
The Cervical Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Cervical Cancer key players involved in developing targeted therapeutics.
• TECENTRIQ (atezolizumab) (Roche)
• Volrustomig (AstraZeneca)
• AL3818 (Advenchen Laboratories)
• ANKTIVA (N-803) (ImmunityBio)
• ZEJULA (niraparib) (Merck/GSK)
• Telaglenastat (Calithera Biosciences)
• JEMPERLI (dostarlimab) + cobolimab (GSK)
• TUKYSA (tucatinib) (Seagen)
• Cadonilimab (Akeso)
• Avutometinib (Verastem)
• LN-145 (Iovance Biotherapeutics)
• Vudalimab (Xencor)
• ENHERTU (trastuzumab deruxtecan) (Daiichi Sankyo/ AstraZeneca)

Stay ahead with the latest insights into breakthrough treatments like AstraZeneca's Volrustomig and Precigen's PRGN-2009, alongside a robust pipeline featuring TECENTRIQ, JEMPERLI, ENHERTU, and more. Get the full Cervical Cancer Pipeline Report here @ Cervical Cancer Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cervical Cancer Therapeutics Assessment
Major key companies are working proactively in the Cervical Cancer Therapeutics market to develop novel therapies which will drive the Cervical Cancer treatment markets in the upcoming years are ADC therapeutics, Roche, AstraZeneca, Precigen, Puma Biotechnology, Iovance Bio therapeutics, Nykode Therapeutics, ISA Pharmaceuticals, Regeneron, Transgene, Daiichi Sankyo, Merck Sharp & Dohme, Genmab/Pfizer, Advenchen Laboratories, ImmunityBio, Calithera Biosciences, Seagen, Akeso, Verastem, Iovance Biotherapeutics, Xencor and Many Others.

Learn more about the emerging Cervical Cancer therapies & key companies @ Cervical Cancer Medication and FDA Approvals - https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cervical Cancer Report Key Insights
1. Cervical Cancer Patient Population
2. Cervical Cancer Market Size and Trends
3. Key Cross Competition in the Cervical Cancer Market
4. Cervical Cancer Market Dynamics (Key Drivers and Barriers)
5. Cervical Cancer Market Opportunities
6. Cervical Cancer Therapeutic Approaches
7. Cervical Cancer Pipeline Analysis
8. Cervical Cancer Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Cervical Cancer Market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.